Summary
This filing represents an amendment to Pfizer Inc.'s (PFE) 10-Q Quarterly Report for the period ending October 1, 1994. While the provided text is primarily navigational and descriptive of the SEC filing's location rather than containing detailed financial statements, it indicates that Pfizer is fulfilling its reporting obligations. Investors should note that the filing date is December 20, 1994, with the reporting period concluding in the third quarter of 1994. The amendment suggests that there may have been a need for clarification or correction to the original filing, which is a common occurrence in regulatory reporting.
Key Highlights
- 1Pfizer Inc. (PFE) filed an amendment to its 10-Q Quarterly Report.
- 2The reporting period covered is the quarter ending October 1, 1994.
- 3The filing was made on December 20, 1994.
- 4This is an amendment (10-Q/A), indicating potential adjustments or clarifications to the original filing.
- 5The filing is accessible through the SEC's EDGAR system under the provided directory path.
- 6The provided text focuses on the administrative aspects of the filing rather than specific financial data.
Frequently Asked Questions
The provided text is a directory listing for the SEC filing and does not contain the actual financial statements or detailed results. To understand Pfizer's financial performance for the quarter ending October 1, 1994, one would need to access the full content of the 10-Q/A filing (e.g., the .txt file) via the EDGAR database.
Amendments to SEC filings, such as this 10-Q/A, are typically filed to correct unintentional errors, clarify previously disclosed information, or to provide additional details that were omitted or misstated in the original filing. It's a mechanism to ensure the accuracy and completeness of the information provided to investors.
The period ending October 1, 1994, means the report covers the financial performance of Pfizer up to the end of the third quarter of 1994. The filing date of December 20, 1994, indicates when the company officially submitted this amended report to the SEC. This timeline is important for understanding the period of operations being reviewed and the recency of the information.